Retrospective Analysis of Blood Biomarkers of Neurological Injury in Human Cases of Viral Infection and Bacterial Sepsis.

Autor:	Bartlett ML; Naval Medical Research Command, Biological Defense Research Directorate, Microbiology and Immunology Department; Ft. Detrick, MD, USA.; Parsons Corporation, Health and Biosciences; Centreville, VA, USA., Goux H; Naval Medical Research Command, Biological Defense Research Directorate, Microbiology and Immunology Department; Ft. Detrick, MD, USA.; Parsons Corporation, Health and Biosciences; Centreville, VA, USA., Johnson L; Naval Medical Research Command, Biological Defense Research Directorate, Microbiology and Immunology Department; Ft. Detrick, MD, USA.; Parsons Corporation, Health and Biosciences; Centreville, VA, USA., Schully KL; Naval Medical Research Command, Biological Defense Research Directorate, ACESO Department; Ft. Detrick, MD, USA., Gregory M; The Austere environments Consortium for Enhanced Sepsis Outcomes, The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., Bethesda, MD, USA., Brandsma J; The Austere environments Consortium for Enhanced Sepsis Outcomes, The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., Bethesda, MD, USA., Chenoweth JG; The Austere environments Consortium for Enhanced Sepsis Outcomes, The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., Bethesda, MD, USA., Clark DV; The Austere environments Consortium for Enhanced Sepsis Outcomes, The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., Bethesda, MD, USA., Rivera LF; Gorgas Memorial Institute, Panama City, Panama.; Carson Centre for Health and Ecosystems Research, La Peñita, Darién, Panama., Lezcano-Coba C; Gorgas Memorial Institute, Panama City, Panama.; Carson Centre for Health and Ecosystems Research, La Peñita, Darién, Panama., Vittor AY; University of Florida, Department of Medicine; Gainesville, FL, USA., Hayes R; Banyan Biomarkers, Gainesville, FL, USA., Galué J; Gorgas Memorial Institute, Panama City, Panama.; Carson Centre for Health and Ecosystems Research, La Peñita, Darién, Panama.; Emerging Infections and Climate Change Research Unit, School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima, Peru., Carrera JP; Gorgas Memorial Institute, Panama City, Panama.; Carson Centre for Health and Ecosystems Research, La Peñita, Darién, Panama.; Department of Biology, University of Oxford, Oxford, United Kingdom., Smith DR; Naval Medical Research Command, Biological Defense Research Directorate, Microbiology and Immunology Department; Ft. Detrick, MD, USA.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2024 Sep 10. Date of Electronic Publication: 2024 Sep 10.
DOI:	10.1093/infdis/jiae445
Abstrakt:	Background: Blood biomarkers of neurological injury could provide a rapid diagnosis of central nervous system (CNS) injury caused by infections. An FDA-approved assay for mild traumatic brain injury (TBI) measures glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), which signal astrocyte and neuronal injury, respectively. Here, we assessed the applicability of this biomarker assay for determining infection-induced brain injury. Methods: We measured serum levels of GFAP and UCH-L1 retrospectively in serum samples from three study populations: 1) human cases infected with Venezuelan equine encephalitis virus (VEEV) and Madariaga virus (MADV) (n = 73), 2) human sepsis patients who were severely ill or diagnosed with encephalitis (n = 66), and 3) sepsis cases that were subsequently evaluated for cognitive impairment (n = 64). Results: In the virus infection group, we found elevated GFAP for VEEV (p = 0.014) and MADV (p = 0.011) infections, which correlated with seizures (p = 0.006). In the bacterial sepsis group, GFAP was elevated in cases diagnosed with encephalitis (p = 0.0007) and correlated with headaches (p = 0.0002). In the bacterial sepsis cases with a later cognitive assessment, elevated GFAP (p = 0.0057) at study enrollment was associated with cognitive impairment six months later with a positive prognostic capacity of 79% (CI: 66-95%; p = 0.0068). Conclusions: GFAP and UCH-L1 levels measured using an FDA-approved assay for TBI may indicate brain injury resulting from viral or bacterial infections and could predict the development of neurological sequelae. (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu